Recommendation of the President – Vyloy (zolbetuximab)
On 2 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 1/2026 on the reimbursement of the medicinal product Vyloy (zolbetuximab) under the B.58 drug program. “Treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach (ICD-10: C15-C16)”